Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treate
- PDF / 1,291,191 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 46 Downloads / 175 Views
ORIGINAL RESEARCH
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIOREAL) Jean-Philippe Lacour . Anthony Bewley . Edward Hammond . Jes B. Hansen . Laura Horne . Carle Paul . Kristian Reich . Julien Seneschal . Clara De Simone . Anne Sohrt . Matthias Augustin . Giovanni Pellacani Received: June 16, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Clinical trials have shown that psoriasis patients who achieve complete skin clearance are more likely to report no
impairment in health-related quality of life (HRQoL) and no psoriasis symptoms versus patients who achieve almost complete skin clearance. However, real-world data are lacking. The objective of this study was to estimate the real-world proportion of moderate-to-severe psoriasis patients on biologic treatment who
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12639260. J.-P. Lacour (&) Department of Dermatology, Archet 2 Hospital, University Hospital of Nice, Nice, France e-mail: [email protected] A. Bewley Department of Dermatology, Barts Health NHS Trust, London, UK A. Bewley Queen Mary School of Medicine, University of London, London, UK
K. Reich SkinflammationÒ Center, Hamburg, Germany J. Seneschal Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin Diseases, Saint-Andre´ Hospital, University of Bordeaux, Bordeaux, France C. De Simone Department of Dermatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario ‘‘A. Gemelli’’ IRCCS, Rome, Italy
J. B. Hansen A. Sohrt LEO Pharma A/S, Ballerup, Denmark
M. Augustin Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany
C. Paul Toulouse University and Larrey Hospital, Toulouse, France
G. Pellacani Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
E. Hammond L. Horne AstraZeneca, Gaithersburg, MD, USA
K. Reich Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Dermatol Ther (Heidelb)
achieved a Psoriasis Symptom Inventory (PSI) total score of 0 (PSI 0; no symptoms) and a Dermatology Life Quality Index (DLQI) score of 0/1 (DLQI 0/1; no impact on HRQoL), and to study the relationship between patient-reported symptoms and HRQoL versus physician-reported psoriasis severity (Psoriasis Area and Severity Index [PASI]). Methods: The PSO-BIO-REAL study was a multinational, prospective, real-world, non-interventional study that included patients aged C 18 years with moderate-to-severe plaque psoriasis who had initiated biologic therapy (either biologic-naı¨ve or had switched biologics [biologic-experienced]). Psoriasis symptoms were evaluated using the PSI, and HRQoL was assessed using the DLQI. Assessments were conducted at baseline a
Data Loading...
